Beyond regulatory delays: How patent misuse impacts access to affordable medications

In this Globe and Mail op-ed from August 2025, Arthritis Consumer Experts calls attention to how brand-name manufacturers are using the patent system to block affordable biosimilars and generics in Canada. The article urges policymakers to modernize patent laws and protect public healthcare budgets.

Click here to download the op-ed.